Literature DB >> 11328669

Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system.

A Cerletti1, J Drewe, G Fricker, A N Eberle, J Huwyler.   

Abstract

Immunoliposomes conjugated with the OX26 monoclonal antibody to the rat transferrin receptor can be used for brain delivery of small molecules. In the present study the uptake of OX26-immunoliposomes by target cells as well as their transcytosis across the blood-brain barrier was investigated. Microscopy of RG2 rat glioma cells incubated with fluorescence labeled OX26-immunoliposomes revealed intracellular co-localization of liposomal cargo, the liposomal membrane bilayer and the OX26 monoclonal antibody. The distinct particulate staining pattern was indicative for accumulation of OX26-immunoliposomes within endosomal or lysosomal compartments. Prolonged incubations demonstrated endosomal release of the liposomal cargo propidium iodide to the cytoplasm. A maximum of 50% of propidium iodide was released from the endosomal compartment after 24 hours of incubation. Transcytosis was studied using an in vitro model of the blood-brain barrier consisting of immortalized RBE4 rat brain endothelial cells. OX26-immunoliposomes did permeate across the RBE4 cell monolayer and showed a permeability coefficient of P(app) = 1.6 x 10(-5) ml/s. Transport was inhibited at low temperature, by competition with free OX26 or by exchanging the OX26 monoclonal antibody for an unspecific isotype antibody. Transcytosis of OX26-immunolipsomes was confirmed in vivo by the brain perfusion and capillary depletion technique. OX26-immunoliposomes were detected within the post-vascular compartment of brain parenchyma (PS product = 2.4 microl/g/min.) and were not associated with the brain microvasculature.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11328669     DOI: 10.3109/10611860008997919

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  26 in total

Review 1.  Drug transport to brain with targeted liposomes.

Authors:  Anita Schnyder; Jörg Huwyler
Journal:  NeuroRx       Date:  2005-01

Review 2.  Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions.

Authors:  Françoise Roux; Pierre-Olivier Couraud
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

Review 3.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

Review 4.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

Review 5.  Targeted therapy for malignant glioma patients: lessons learned and the road ahead.

Authors:  Tiffany T Huang; Shawn M Sarkaria; Timothy F Cloughesy; Paul S Mischel
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 6.  Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems.

Authors:  Patrick M Glassman; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2019-03-05       Impact factor: 4.030

Review 7.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

8.  Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.

Authors:  Andrea Orthmann; Reiner Zeisig; Regine Süss; Dorothea Lorenz; Margit Lemm; Iduna Fichtner
Journal:  Pharm Res       Date:  2012-03-08       Impact factor: 4.200

Review 9.  Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma.

Authors:  Jun Yoshida; Masaaki Mizuno
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

10.  Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.

Authors:  Anita Schnyder; Stefan Krähenbühl; Michael Török; Jürgen Drewe; Jörg Huwyler
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.